Septic ShockPhase 4NCT06224881
Vitamin C Deficiency in Septic Shock
A Phase 4 study testing Ascorbic acid in people with Septic Shock, run by Cairo University at 1 site in Egypt.
Trial summary
Objectives: investigators aim to study the effect of addition of vitamin C as a part of treatment in septic shock patients on: Hemodynamics, Inflammation status and ICU outcome. Subjects and methods: A prospective interventional randomized cohort study, was conducted on 150 consecutive patients who were admitted to… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Septic Shock
- What is being tested?
- Ascorbic acid
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 150 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Dec 2021to 31 Jan 2023
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Septic shock (defined by sepsis induced hypotension i.e. MAP < 65 mmHg, tissue hypo-perfusion, vasopressors
Who cannot join
- Age below 18 years old
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Treating Vitamin C Deficiency in Septic Shock: Would it Help?
Objectives: investigators aim to study the effect of addition of vitamin C as a part of treatment in septic shock patients on: Hemodynamics, Inflammation status and ICU outcome.
Subjects and methods: A prospective interventional randomized cohort study, was conducted on 150 consecutive patients who were admitted to the ICU with septic shock based on SIRS, SOFA and APACHE II. Treatment group (n=75) had given ascorbic acid (Vitamin C) parenterally 6gm daily and control group (n=75). Measuring the level of Vitamin C in all study population (normal range 50-70 μM/L) before and after period of 4 days.
Read the detailed description
AIM OF THE WORK investigators aim to study the effect of addition of vitamin C in septic shock patients on:
- Mean arterial pressure
- C-reactive protein as an inflammatory marker
- Vasopressors ( norepinephrine) dose and duration.
- ICU outcome ( ICU stay, 7 and 28 days mortality)
SUBJECTS AND METHODS
Study type A prospective interventional randomized cohort study carried out at Critical Care Department, Cairo University Hospitals with 25 ICU beds for medical and surgical patients, in the period between December 2021 to January 2023.
An informed consent from 1st degree relatives was taken and confidentiality of information was assured.
Permission from the faculty of medicine ethical committee was obtained. Ethical committee approval number: MS-362-2019
Study design of the study population The patients' demographic data (including age, sex, baseline diseases, and causes of ICU admission) were extracted from their medical charts, and the patients' clinical characteristics (such as vital signs and hemodynamic parameters) were monitored as daily interval.
Laboratory data such as serum electrolyte concentrations, serum creatinine levels were extracted from the patients' medical charts.
Vit C level was measured for all patients (normal range 50-70 μM/L).
The patients' Acute Physiology and Chronic Health Evaluation II (APACHE II) and sequential organ failure assessment (SOFA) scores were calculated at the time of admission.
Patients were randomly divided into 2 groups into:
- Treatment group (n=75) B) Control group (n=75) Ascorbic acid (Vitamin C) was given parenterally for the treatment group (2 gm every 8hrs) for 4 days.
Remeasuring the level of Vitamin C in all study population after 4 days.
- Measurement and administration of Vitamin C Vitamin C (Ascorbic Acid) parenteral formula Manufacturer: Arco Life sciences ( Http://www.arcolifesciences.co.in/ ) Ampules: each ampule contains 500 mg of ascorbic acid (5 ml each 1 ml contains 100mg) The dose and duration of intervention were selected based on the literature review.
Each dose of ascorbic acid was diluted in 50 ml of dextrose 5% solution and was administered as intravenous infusion over 30 minutes.
During the study period, patients were followed for any ascorbic acid-related adverse effects including nausea, vomiting, abdominal pain, hematuria, flushing, and significant arterial blood pressure change.
Measurement Kits This kit is an Enzyme-Linked Immunosorbent Assay (ELISA). The plate has been pre-coated with human Vitamin C antibody (VC). VC present in the sample is added and binds to antibodies coated on the wells. Substrate solution is then added and color develops in proportion to the amount of human VC and absorbance is measured at 450 nm.
- Manufacturer Bioassay Technology Labs
- Serial number: E1538Hu
- Standard Curve Range: 200 Mg/ml - 300 Mg/ml
- Sensitivity: 0.52 Mg/ml
- Size: 96 wells
- Storage: Store the reagents at 2-8°C. For over 6-month storage refer to the expiration date keep it at -20°C. Avoid repeated thaw cycles. If individual reagents are opened it is recommended that the kit be used within 1 month.
- Specimen Collection Serum Allow serum to clot for 10-20 minutes at room temperature. Centrifuge at 2000-3000 RPM for 20 minutes Plasma Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples for 15 minutes at 2000-3000 RPM at 2 - 8°C within 30 minutes of collection.
- Calculation of results :
Plasma vitamin C level were measured by Vitamin C ELISA Kits by microgram /milliliter (μg/ml) and calculated to micromole/ L (μM/L) in factor of 5.6679 and results were given accordingly
- Normal range of Vitamin C in plasma : Multiple ranges are given in the level of vitamin C but recent studies consider range of (50-70μ M/L) is the reference in patients with sepsis and septic shock .
Statistical analysis Analysis of data was done using Statistical Program for Social Science version 20 (SPSS Inc., Chicago, IL, USA). Quantitative variables were described in the form of mean and standard deviation. Qualitative variables were described as number and percent. In order to compare parametric quantitative variables between two groups, Student t test was performed. Qualitative variables were compared using chi-square (X2) test or Fisher's exact test when frequencies were below five. Pearson correlation coefficients were used to assess the association between two normally distributed variables. When a variable was not normally distributed, A P value < 0.05 is considered significant The used tests were Chi-square test For categorical variables, to compare between different groups, Fisher's Exact or Monte Carlo correction for chi-square when more than 20% of the cells have expected count less than 5,Student t-test For normally distributed quantitative variables, to compare between two studied groups, ANOVA with repeated measures for normally distributed quantitative variables, to compare between more than two periods or stages, and Post Hoc test (Bonferroni adjusted) for pairwise comparisons, Pearson coefficient To correlate between two normally distributed quantitative variables, Mann Whitney test For abnormally distributed quantitative variables, to compare between two studied groups, Friedman test For abnormally distributed quantitative variables, to compare between more than two periods or stages and Post Hoc Test (Dunn's) for pairwise comparisons and Q: Cochran's test For non-parametric test for binary response variable and Post Hoc Test (Dunn's) for pairwise comparisons.
- Conditions
- Septic Shock
- Being tested
- Ascorbic acid
- Medical subject headings
- Shock, Septic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ascorbic acidDrug
2 gm every 8hrs for 4 days
| Study group | Role | What they receive |
|---|---|---|
| Vitamin C group | Active comparator | Ascorbic acid (Vitamin C) was given parenterally (2 gm every 8hrs) for 4 days. Receives: Drug: Ascorbic acid |
| Control group | Placebo comparator | No vit C given Receives: Drug: Ascorbic acid |
What is being measured
The primary outcome is the main question the study is designed to answer.
C-reactive protein
C-reactive protein level III- Vasopressor (noradrenaline) dose and duration
Measured: Evaluated on a daily basis for 4 days
Mean arterial blood pressure
Mean arterial blood pressure (MAP).
Measured: Evaluated on a daily basis for 4 days
Secondary outcomes (2)
ICU Length of stay . II- 7 day mortality rate. III- 28 days mortality
ICU Length of stay II- 7 day mortality rate. III- 28 days mortality
Measured: 28 days
ICU mortality
ICU mortality
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2024
- Study start1 Dec 2021
- Primary completion31 Jan 2023
- Study completion31 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Septic ShockStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mostafa Farouk, Cairo University
- Investigators
- Mohamed Ashraf, MD, Study director, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06224881
- Sponsor's protocol ID
- MS-362-2019
- Status last verified
- Jan 2024
- First submitted
- 28 Dec 2023
- Last updated
- 25 Jan 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treating Vitamin C Deficiency in Septic Shock: Would it Help?
- ClinicalTrials.gov ID
- NCT06224881
- Acronym / sponsor ID
- MS-362-2019
- Conditions
- Septic Shock
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 1 Dec 2021 (actual)
- Primary completion
- 31 Jan 2023 (actual)
- Study completion
- 31 Jan 2023 (actual)
- First posted
- 25 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objectives: investigators aim to study the effect of addition of vitamin C as a part of treatment in septic shock patients on: Hemodynamics, Inflammation status and ICU outcome.
Subjects and methods: A prospective interventional randomized cohort study, was conducted on 150 consecutive patients who were admitted to the ICU with septic shock based on SIRS, SOFA and APACHE II. Treatment group (n=75) had given ascorbic acid (Vitamin C) parenterally 6gm daily and control group (n=75). Measuring the level of Vitamin C in all study population (normal range 50-70 μM/L) before and after period of 4 days.
Detailed description
AIM OF THE WORK investigators aim to study the effect of addition of vitamin C in septic shock patients on:
- Mean arterial pressure
- C-reactive protein as an inflammatory marker
- Vasopressors ( norepinephrine) dose and duration.
- ICU outcome ( ICU stay, 7 and 28 days mortality)
SUBJECTS AND METHODS
Study type A prospective interventional randomized cohort study carried out at Critical Care Department, Cairo University Hospitals with 25 ICU beds for medical and surgical patients, in the period between December 2021 to January 2023.
An informed consent from 1st degree relatives was taken and confidentiality of information was assured.
Permission from the faculty of medicine ethical committee was obtained. Ethical committee approval number: MS-362-2019
Study design of the study population The patients' demographic data (including age, sex, baseline diseases, and causes of ICU admission) were extracted from their medical charts, and the patients' clinical characteristics (such as vital signs and hemodynamic parameters) were monitored as daily interval.
Laboratory data such as serum electrolyte concentrations, serum creatinine levels were extracted from the patients' medical charts.
Vit C level was measured for all patients (normal range 50-70 μM/L).
The patients' Acute Physiology and Chronic Health Evaluation II (APACHE II) and sequential organ failure assessment (SOFA) scores were calculated at the time of admission.
Patients were randomly divided into 2 groups into:
- Treatment group (n=75) B) Control group (n=75) Ascorbic acid (Vitamin C) was given parenterally for the treatment group (2 gm every 8hrs) for 4 days.
Remeasuring the level of Vitamin C in all study population after 4 days.
- Measurement and administration of Vitamin C Vitamin C (Ascorbic Acid) parenteral formula Manufacturer: Arco Life sciences ( Http://www.arcolifesciences.co.in/ ) Ampules: each ampule contains 500 mg of ascorbic acid (5 ml each 1 ml contains 100mg) The dose and duration of intervention were selected based on the literature review.
Each dose of ascorbic acid was diluted in 50 ml of dextrose 5% solution and was administered as intravenous infusion over 30 minutes.
During the study period, patients were followed for any ascorbic acid-related adverse effects including nausea, vomiting, abdominal pain, hematuria, flushing, and significant arterial blood pressure change.
Measurement Kits This kit is an Enzyme-Linked Immunosorbent Assay (ELISA). The plate has been pre-coated with human Vitamin C antibody (VC). VC present in the sample is added and binds to antibodies coated on the wells. Substrate solution is then added and color develops in proportion to the amount of human VC and absorbance is measured at 450 nm.
- Manufacturer Bioassay Technology Labs
- Serial number: E1538Hu
- Standard Curve Range: 200 Mg/ml - 300 Mg/ml
- Sensitivity: 0.52 Mg/ml
- Size: 96 wells
- Storage: Store the reagents at 2-8°C. For over 6-month storage refer to the expiration date keep it at -20°C. Avoid repeated thaw cycles. If individual reagents are opened it is recommended that the kit be used within 1 month.
- Specimen Collection Serum Allow serum to clot for 10-20 minutes at room temperature. Centrifuge at 2000-3000 RPM for 20 minutes Plasma Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge samples for 15 minutes at 2000-3000 RPM at 2 - 8°C within 30 minutes of collection.
- Calculation of results :
Plasma vitamin C level were measured by Vitamin C ELISA Kits by microgram /milliliter (μg/ml) and calculated to micromole/ L (μM/L) in factor of 5.6679 and results were given accordingly
- Normal range of Vitamin C in plasma : Multiple ranges are given in the level of vitamin C but recent studies consider range of (50-70μ M/L) is the reference in patients with sepsis and septic shock .
Statistical analysis Analysis of data was done using Statistical Program for Social Science version 20 (SPSS Inc., Chicago, IL, USA). Quantitative variables were described in the form of mean and standard deviation. Qualitative variables were described as number and percent. In order to compare parametric quantitative variables between two groups, Student t test was performed. Qualitative variables were compared using chi-square (X2) test or Fisher's exact test when frequencies were below five. Pearson correlation coefficients were used to assess the association between two normally distributed variables. When a variable was not normally distributed, A P value < 0.05 is considered significant The used tests were Chi-square test For categorical variables, to compare between different groups, Fisher's Exact or Monte Carlo correction for chi-square when more than 20% of the cells have expected count less than 5,Student t-test For normally distributed quantitative variables, to compare between two studied groups, ANOVA with repeated measures for normally distributed quantitative variables, to compare between more than two periods or stages, and Post Hoc test (Bonferroni adjusted) for pairwise comparisons, Pearson coefficient To correlate between two normally distributed quantitative variables, Mann Whitney test For abnormally distributed quantitative variables, to compare between two studied groups, Friedman test For abnormally distributed quantitative variables, to compare between more than two periods or stages and Post Hoc Test (Dunn's) for pairwise comparisons and Q: Cochran's test For non-parametric test for binary response variable and Post Hoc Test (Dunn's) for pairwise comparisons.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vitamin C group | Active comparator | Drug: Ascorbic acidAscorbic acid (Vitamin C) was given parenterally (2 gm every 8hrs) for 4 days. |
| Control group | Placebo comparator | Drug: Ascorbic acidNo vit C given |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Septic shock (defined by sepsis induced hypotension i.e. MAP < 65 mmHg, tissue hypo-perfusion, vasopressors
Key exclusion criteria (1 listed)
- Age below 18 years old
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ascorbic acid2 gm every 8hrs for 4 days | Drug | Control group, Vitamin C group |
Primary outcome
C-reactive protein
Time frame: Evaluated on a daily basis for 4 days
C-reactive protein level III- Vasopressor (noradrenaline) dose and duration
Mean arterial blood pressure
Time frame: Evaluated on a daily basis for 4 days
Mean arterial blood pressure (MAP).
2 secondary outcomes
ICU Length of stay . II- 7 day mortality rate. III- 28 days mortality
Time frame: 28 days
ICU mortality
Time frame: 28 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Septic Shock
RecruitingObservational study
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Sepsis
Not yet recruitingObservational study
Serum GDF-15 and LGALS3BP as Prognostic Biomarkers in Sepsis
Sepsis, Septic Shock
RecruitingPhase 3
A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone, Evaluating Survival and Functional Recovery and the Influence of Transcriptomic Response
Septic Shock
RecruitingObservational study
Clinical Value of EMR3 in Sepsis Diagnosis, Monitoring, and Prognosis: A Multicenter Prospective Observational Study
Sepsis
Not yet recruiting
Hemodynamic Resuscitation Guided by Non-Invasive Mean Systemic Filling Pressure to Prevent Acute Kidney Injury in Septic Shock
Acute Kidney Injury Due to Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed Ashraf, MD study director
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Ascorbic acid in people with Septic Shock, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
C-reactive protein (time frame: Evaluated on a daily basis for 4 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2024.